ERK activation is a common feature of tumors with a K-Ras, N-Ras, or B-Raf mutation [263], and the inhibition of the Raf/MEK/ERK pathway was supposed to be effective in cancers harboring mutations in these genes [264]. This evidence concerns the gene KRAS and cancer.